Figures below are as of 21 Jul 2026. GMP is an unofficial, unregulated indicator of grey-market demand and is not investment advice.
| Grey Market Premium (GMP) | ₹15 |
| Estimated listing gain | +34.9% |
| Estimated listing price | ₹58 |
| Issue price | ₹43 |
| Issue size | ₹11.61 Cr |
| Subscription | 840.74x |
| Open date | 12 May 2026 |
| Close date | 14 May 2026 |
| Listing date | 19 May 2026 |
| Listing at | BSE SME |
| IPO type | SME |
| Registrar | Bigshare Services Pvt.Ltd. |
As of 21 Jul 2026, the grey market premium (GMP) for the Goldline Pharmaceutical Ltd. IPO is ₹15, implying an estimated listing gain of about +34.9% and an estimated listing price near ₹58. GMP is unofficial and unregulated — it indicates grey-market sentiment, not a guaranteed listing price.
The Goldline Pharmaceutical Ltd. IPO is open for subscription from 12 May 2026 to 14 May 2026. It is expected to list on 19 May 2026.
The Goldline Pharmaceutical Ltd. IPO is priced at ₹43 per share, with a total issue size of ₹11.61 Cr.
As of 21 Jul 2026, the Goldline Pharmaceutical Ltd. IPO is subscribed 840.74x.